indapamide + levamlodipine

**Indapamide + levamlodipine** is a fixed-dose combination of two antihypertensive agents: **indapamide**, a thiazide-like diuretic, and **levamlodipine**, the S-enantiomer of amlodipine, a dihydropyridine calcium channel blocker. Indapamide acts primarily at the distal convoluted tubule in the kidney, increasing urinary excretion of sodium and water, thus reducing plasma volume and lowering blood pressure. Levamlodipine, as a calcium channel blocker, inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and decreased peripheral vascular resistance, which lowers blood pressure. This combination is intended for the management of hypertension, leveraging additive antihypertensive effects from two complementary mechanisms of action. Similar combinations with amlodipine (the racemic mixture) exist and are widely approved for hypertension, but the specific pairing of indapamide with the S-enantiomer levamlodipine may offer improved efficacy and/or tolerability profiles compared to the racemic form, though large-scale regulatory approvals and brand names for this specific combination are not widely documented.

Brand names

LENINGRADO 5LENINGRADO5LENINGRADO-5

Other names

LENINGRADO 5 associationLENINGRADO5 associationLENINGRADO-5 association